Clinical Research Directory

Inclusion Criteria: 1. Participant and/or parent/guardian must understand and provide written informed consent and assent. 2. Aged 4 to 55 years per applicable enrolling group below of any sex/race/ethnicity at informed consent and assent (if applicable) form signature: 1. Group 1: Adults; ages 18-55 years 2. Group 2: Adolescents; ages 12-17 years 3. Group 3: Children; ages 4-11 years 3. A physician-confirmed medical history of peanut allergy within minutes to 2 hours of ingesting peanut. 4. A peanut SPT with mean wheal diameter as defined by age. Exclusion Criteria: 1. Laboratory evidence of liver or renal disease. 2. Poorly controlled or severe asthma/wheezing 3. Previous use of any form of peanut allergen immunotherapy within the 6 months prior to Screening. 4. Previous use of any biologic therapies such as omalizumab, dupilumab, benralizumab, reslizumab, tezepelumab, or any other immunomodulatory or immunosuppressive therapy (not including corticosteroids) within the 6 months prior to Screening. 5. Current use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), or calcium channel blockers. 6. Treatment with a burst of oral, intramuscular (IM), intra-articular (IA), or intravenous (IV) steroids of more than two days within 30 days of Screening. 7. Unable to temporarily discontinue antihistamines (5 half-lives of the antihistamine) prior to SPT. 8. Unable to discontinue topical steroids to the testing application site for 24 hours prior to testing. Other inclusion/exclusion criteria apply.